Kura Oncology (KURA) Operating Expenses (2013 - 2026)

Kura Oncology (KURA) has 14 years of Operating Expenses data on file, last reported at $97.1 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $97.1 million, up 23.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.1 million (down 64.23% YoY), and the FY2025 annual result was $371.1 million, up 50.2% from the prior year.
• Operating Expenses improved to $97.1 million in Q1 2026 per KURA's latest filing, from $78.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $97.1 million in Q1 2026 and troughed at $32.8 million in Q1 2022.
• A 5-year average of $52.0 million and a median of $44.6 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses rose 5.01% in 2022, then jumped 63.25% in 2024.
• A 5-year view of Operating Expenses shows it stood at $35.2 million in 2022, then surged by 33.01% to $46.8 million in 2023, then soared by 63.25% to $76.3 million in 2024, then increased by 3.24% to $78.8 million in 2025, then climbed by 23.19% to $97.1 million in 2026.
• Business Quant data shows KURA's Operating Expenses at $97.1 million in Q1 2026, $78.8 million in Q1 2025, and $76.3 million in Q4 2024.